These highlights do not include all the information needed to use valsartan and hydrochlorothiazide tablets safely and effectively. See full prescribing information for valsartan and hydrochlorothiazide tablets.
VALSARTAN and HYDROCHLOROTHIAZIDE tablets USP, for oral use
Initial U.S. Approval: 1998
WARNING: FETAL TOXICITY
See full prescribing information for complete boxed warning.
-
•
-
When pregnancy is detected, discontinue valsartan and hydrochlorothiazide tablets as soon as possible. (5.1)
-
•
-
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)
INDICATIONS AND USAGE
Valsartan and hydrochlorothiazide is the combination tablet of valsartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ), a diuretic. Valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure:
-
•
-
In patients not adequately controlled with monotherapy ( 1)
-
•
-
As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1)
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
DOSAGE AND ADMINISTRATION
-
•
-
Dose once daily. Titrate as needed to a maximum dose of 320 mg/25 mg ( 2)
-
•
-
May be used as add-on/switch therapy for patients not adequately controlled on any of the components (valsartan or HCTZ) ( 2)
-
•
| 以下是“全球医药”详细资料 |
|
|
